MAPK3 and lung cancer: Aberrant activation of phosphorylated Erk1/2 induced by lncRNAs has been observed in most types of cancers, including glioma [20], gastric cancer [21], lung cancer [22], hepatocellular carcinoma [23], gallbladder cancer [24], and melanoma [25].